This application, "Imaging Software of Functional Connectivity MRI for Alzheimer's Disease", is written in response to (PA-11-134) "Lab to Marketplace: Tools for Brain and Behavioral Research (SBIR [R43/R44])". Alzheimer's disease (AD) is the most common form of dementia. However, developing drugs that effectively slow or alter the course of Alzheimer's disease has proven to be notoriously difficult. Academic and pharmaceutical scientists believe that a large part of the problem is that they are testing these drugs at the late stage in the progression of the disease, when damage to the brain is too severe to make intervention effective. Therefore, commercial AD biomarkers for early detection are of paramount importance in analyzing disease progression, yielding an accurate diagnosis and providing efficacy assessment following treatment in clinical trials and drug discovery. The goal of this SBIR Phase II application is to commercialize innovative neuroimaging technology tool, called Resting-state functional connectivity MRI (R-fcMRI), for the marketplace based on a decade of Alzheimer's research progress supported by the National Institues of Health in the laboratory of Shi-Jiang Li, Ph.D., and Alzheimer's Disease NeuroImaging Initiative (ADNI 2) program, and other neuroimaging labs. We will retrospectively and prospectively collect R-fcMRI imaging datasets from national and international multicenter studies to validate our commercial BS-GFC software product in order to provide a robust and reliable biomarker for assisting in the prediction of AD onset, diagnosis and assessment of treatment efficacy.

Public Health Relevance

Alzheimer's disease (AD) is the most common form of dementia. As many as 5.3 million Americans are suffering from Alzheimer disease (AD), and it costs the country around $148 billion a year to provide care. Today, it is the sixth leading cause of death and is expected to rise as the Baby Boomer generation ages. That figure is expected to balloon worldwide in the coming decades. However, it has been notoriously difficult to develop drugs that effectively slow or alter the course of Alzheimer's disease, because of the lack of commercial AD biomarkers that have the potential for early disease detection, accurate diagnosis and efficacy assessment in following treatment in clinical trials and drug discovery. The goal of this SBIR Phase II application is commercializing innovative neuroimaging technology tools, called Resting-state functional connectivity MRI (R-fcMRI), for the marketplace based on a decade of research progress in Alzheimer's disease research supported by the National Institue of Aging, a division of the National Institutes of Health, in the laboratory of Si-Jiang Li, Ph.D., and renewed Alzheimer's Disease NeuroImaging Initiative (ADNI 2) program and other neuroimaging labs. We will retrospectively and prospectively collect MRI/fcMRI imaging datasets from national and international multicenter studies to validate our commercial BS-GFC software product in order to provide a robust and reliable biomarker for assisting in the prediction of AD onset, diagnosis and assessment of treatment efficacy.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AG035405-02A1
Application #
8456091
Study Section
Special Emphasis Panel (ZRG1-ETTN-K (10))
Program Officer
Hsiao, John
Project Start
2010-08-15
Project End
2016-05-31
Budget Start
2013-07-01
Budget End
2014-05-31
Support Year
2
Fiscal Year
2013
Total Cost
$598,020
Indirect Cost
Name
Brainsymphonics, LLC
Department
Type
DUNS #
830044439
City
New Berlin
State
WI
Country
United States
Zip Code
53151